吉林敖东药业集团股份有限公司 二〇二三年度独立董事述职报告 述职人：李鹏 本人作为吉林敖东药业集团股份有限公司（以下简称"公司"）的独立董事， 董事会提名委员会的主任、薪酬与考核委员会成员，在 2023 年度任职期间，本 人严格按照《公司法》《证券法》《吉林敖东药业集团股份有限公司章程》(以下 简称"《公司章程》")《上市公司独立董事管理办法》《独立董事工作细则》等法 律法规、规范性文件的规定和要求，积极出席公司召开的相关会议,认真审议会 议各项议案,坚持促进公司规范运作，对公司相关事项发表独立意见,恪尽职守、 勤勉尽责，充分发挥独立董事作用,切实维护了公司及全体股东特别是中小股东 的利益。现将 2023 年度本人履行独立董事职责情况报告如下： 一、基本情况 本人基本情况：1982 年 1 月出生，硕士研究生。2006 年 9 月至 2007 年 5 月任隆安（上海）律师事务所执业律师，2007 年 6 月至 2014 年 8 月任国浩律师 （上海）事务所执业律师，2014 年 8 月至今任国浩律师（上海）事务所无限合 伙人。其间：2014 年 3 月至 2018 年 4 月任宁波海天精工股份有限公司（股票代 ...

证券代码：000623 证券简称：吉林敖东 公告编号：2024-035 吉林敖东药业集团股份有限公司 2023 年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求 （2022 年修订）》及相关规定，将本公司 2023 年度募集资金存放与实际使用情 况专项说明如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于核准吉林敖东药业集团股份有限公司公开 发行可转换公司债券的批复》（证监许可[2018]184 号）核准，吉林敖东药业集 团股份有限公司（以下简称"公司"）于 2018 年 3 月 13 日公开发行了面值总额 241,300 万元的可转换公司债券，扣除发行费用 2,446.13 万元后，募集资金净 额为 238,853.87 万元。截至 2018 年 3 月 19 日，上述募集资金已经到位。中准 会计师事务所（特殊普通合伙）已对上述募 ...

Financial Performance - The company reported a non-operating income of ¥35,522,895.57 from the disposal of non-current assets in 2023, a significant increase from ¥1,486,450.08 in 2022[29]. - Government subsidies recognized in the current period amounted to ¥94,193,045.36, up from ¥82,482,380.98 in the previous year, indicating a growth of approximately 9.8%[29]. - The company achieved a profit of ¥118,563,625.81 from investments where the cost was less than the fair value of identifiable net assets acquired, compared to ¥610,907,708.05 in 2022[29]. - The total impact of non-recurring gains and losses after tax and minority interests was reported as ¥146,524,768.26, reflecting a decrease from the previous year's figures[29]. - The company's operating revenue for 2023 reached ¥3,449,123,301.81, representing a 20.25% increase compared to ¥2,868,211,464.89 in 2022[45]. - The net profit attributable to shareholders decreased to ¥1,459,879,678.96, down 18.02% from ¥1,780,642,529.11 in the previous year[45]. - The net cash flow from operating activities was ¥1,313,354,910.70, a decline of 15.63% compared to ¥1,530,399,881.11 in 2022[45]. - Basic earnings per share fell to ¥1.2971, down 17.35% from ¥1.5692 in 2022[45]. - Total assets increased by 3.48% to ¥32,266,140,600.63 from ¥31,172,579,530.80 at the end of 2022[45]. - The net assets attributable to shareholders rose by 4.52% to ¥27,211,602,992.20 from ¥26,036,584,656.86 at the end of 2022[45]. Market Trends and Opportunities - The global pharmaceutical market is projected to exceed $2 trillion by 2028, with a compound annual growth rate of 4.8% from 2022 to 2028[55]. - The global chemical drug market accounted for 74.2% of the pharmaceutical market in 2023, while the biological drug market held 25.8%[55]. - The average price reduction for newly negotiated drugs in the national medical insurance directory was 60.1%[58]. - The company is expected to benefit from the "Belt and Road" initiative, which will enhance the international market for traditional Chinese medicine[57]. Product Development and Innovation - The company has established a multi-wheel-driven development model encompassing "pharmaceuticals + finance + health" and is expanding into health food and agriculture sectors[66]. - The company is committed to enhancing the quality of its products and accelerating technological innovation in the pharmaceutical industry[64]. - The company's pharmaceutical and retail business achieved revenue of 2,983.48 million yuan, accounting for 86.50% of total revenue, with a year-on-year growth of 20.97%[97]. - The traditional Chinese medicine (TCM) segment saw a revenue increase of 27.19% year-on-year, focusing on three core product clusters[97]. - The company has 616 production approval numbers, including 311 for TCM and 305 for chemical drugs, with 47 unique products and formulations[99]. - The company is focusing on expanding its product line with new formulations such as Qihuang Yishen Oral Liquid and Tian'e Buxin Oral Liquid, targeting kidney health and energy restoration[100]. - The company emphasizes the importance of regulatory approvals, as seen with the National Drug Approval Numbers for its products, ensuring market readiness[100]. - Future product development will likely focus on enhancing existing formulations and introducing innovative health solutions to meet consumer demand[100]. - The company is committed to research and development, aiming to improve product efficacy and expand its therapeutic applications[100]. Sales and Market Expansion - The company has launched several proprietary products aimed at various health conditions, including Danxiang Qingzi Granules for hyperlipidemia and Du Zhi Wan for ischemic stroke recovery[100]. - The company is actively pursuing market expansion strategies, particularly in the herbal medicine sector, to enhance its competitive edge[100]. - The company has established a standardized procurement process to enhance quality and efficiency, aiming to reduce costs while ensuring timely supply of materials[107]. - The company expanded its retail presence by adding 19 new 24-hour pharmacies and establishing online stores on major e-commerce platforms[172]. - The company plans to enhance its market coverage and share through strategic product development and marketing initiatives in pediatric and gynecological fields[185]. Corporate Governance and Compliance - The company emphasized the importance of risk awareness regarding forward-looking statements made in the report, urging investors to understand the differences between plans, forecasts, and commitments[15]. - The company’s financial report for the year shows a commitment to transparency, with all board members present for the report's review[4]. - The company has maintained its continuous supervision responsibilities through its appointed sponsor institution during the reporting period[11]. - The company continues to focus on quality management, adhering to higher internal control standards than national regulations[145]. - The company is committed to ensuring the efficacy and safety of its products through rigorous testing and compliance with regulatory standards[134]. Recognition and Achievements - The company has been recognized as a "Chinese Time-honored Brand" by the Ministry of Commerce, reflecting its historical significance and market presence[66]. - The brand "Aodong" has been recognized as one of the "Top 500 Most Valuable Brands in China" for 18 consecutive years, with a brand value of ¥131.94 billion[114]. - The company has received numerous honors, including being recognized as a national high-tech enterprise and a model for harmonious labor relations[96].

一、募集资金基本情况 证券代码:000623 证券简称:吉林敖东 公告编号: 2024-036 吉林敖东药业集团股份有限公司 关于募投项目结项并将节余募集资金 永久补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林敖东药业集团股份有限公司（以下简称"公司"）于 2024 年 4 月 16 日召开第十一届董事会第九次会议和第十一届监事会第八次会议审议通过《关于 募投项目结项并将节余募集资金永久补充流动资金的议案》，同意公司将"吉林 敖东延边药业股份有限公司扩建升级项目二期工程项目"予以结项，并将节余募 集资金 3,747.98 万元永久补充流动资金（实际金额以资金转出当日专户余额为 准）。 根据《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》以及公司《募集资金管理办法》等相关规定，因本次拟结项的"吉林敖东 延边药业股份有限公司扩建升级项目二期工程项目"的节余资金占对应项目募 集资金净额比例未超过 10%，该事项为公司董事会审批权限，无需提交股东大会 审议。现将具体情况公告如下： 1、募集资金到位情况 经中国证券监督 ...

吉林敖东药业集团股份有限公司 2023 年度募集资金存放与使用情况 鉴证报告 中准会计师事务所（特殊普通合伙） Zhongzhun Certified Public Accountants (电话)TEL: (010)88356126 (传真)FAX: (010)88354837 (邮编)POSTCODE: 100044 (地址)ADDRESS: 北京市海淀区首体南路 22 号楼 4 层 中准会计师事务所（特殊普通合伙） Zhongzhun Certified Public Accountants 关于吉林敖东药业集团股份有限公司 2023 年度募集资金存放与使用情况的 吉林敖东药业集团股份有限公司全体股东： 我们接受委托，对后附的吉林敖东药业集团股份有限公司（以下简称"吉林敖东"） 2023 年度募集资金存放与使用情况专项报告（以下简称"募集资金专项报告"）执行 了合理保证的鉴证业务。 一、董事会的责任 吉林敖东董事会的责任是按照中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕 15 号）、《深圳证券交易所上市公司自律监 ...

吉林敖东药业集团股份有限公司章程 吉林敖东药业集团股份有限公司 章 程 （经 2024 年 4 月 16 日召开的 2024 年第一次临时股东大会审议通过） 2024 年 4 月 | 第三节 会计师事务所的聘任 | 38 | | --- | --- | | 第九章 通知和公告 | 39 | | 第一节 通知 | 39 | | 第二节 公告 | 40 | | 第十章 合并、分立、增资、减资、解散和清算 | 40 | | 第一节 合并、分立、增资和减资 | 40 | | 第二节 解散和清算 | 41 | | 第十一章 修改章程 | 42 | | 第十二章 附则 | 43 | 吉林敖东药业集团股份有限公司章程 第一章 总则 | | | 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为，根据《中华 人民共和国公司法》(以下简称《公司法》)《中华人民共和国证券法》(以下简称《证券法》) 和其他有关规定，制订本章程。 | 目 录 | 1 | | --- | --- | | 第一章 总则 | 3 | | 第二章 经营宗旨和范围 | 4 | | 第三章 股份 | 4 | | 第一节 股份发行 | 4 | | ...

根据公司财务报告内部控制重大及重要缺陷的认定情况，于内部控制自我评 价报告基准日，公司不存在财务报告内部控制重大、重要缺陷，董事会认为，公 司已按照企业内部控制规范体系和相关规定的要求在所有重大方面保持了有效 的财务报告内部控制。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制自我评价报告是公司董事会的责任。监事会对董事 会建立和实施内部控制进行监督。经营管理层负责组织领导企业内部控制的日常 运行。 公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任 何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性 承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部 控制评价结果推测未来内部控制的有效性具有一定的风险。 二、内部控制评价结论 吉林敖东药业集团股份有限公司 2 ...

证券代码:000623 证券简称:吉林敖东 公告编号: 2024-039 吉林敖东药业集团股份有限公司 关于聘任证券事务代表的公告 特此公告。 吉林敖东药业集团股份有限公司董事会 2024 年 4 月 17 日 1 联系电话：0433－6238973 联系传真：0433－6238973 电子信箱：000623@jlaod.com 联系地址：吉林省敦化市敖东大街 2158 号 附件：赵仁和先生简历 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 吉林敖东药业集团股份有限公司（下称"公司"）于 2024 年 4 月 16 日召开 第十一届董事会第九次会议，审议通过了《关于聘任公司证券事务代表的议案》， 同意聘任赵仁和先生担任公司证券事务代表，协助董事会秘书履行职责，任期自 董事会审议通过之日起至第十一届董事会任期届满之日止。 赵仁和先生已取得深圳证券交易所颁发的《上市公司董事会秘书培训证明》， 熟悉履职相关的法律法规、具备与岗位要求相适应的职业操守和从业经验，其任 职资格符合《深圳证券交易所股票上市规则》等相关法律法规的有关规定。 赵仁和先生简历详见附件，其联系方式 ...

证券代码：000623 证券简称：吉林敖东 公告编号：2024-029 吉林敖东药业集团股份有限公司 关于召开2024年第一次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要提示： 1.吉林敖东药业集团股份有限公司已于2024年3月19日发布《关于召开2024 年第一次临时股东大会的通知》（公告编号：2024-028），为进一步保护投资者 的合法权益，方便股东行使股东大会表决权，现发布《关于召开2024年第一次临 时股东大会的提示性公告》。 2.本次股东大会采取现场投票与网络投票相结合的方式。 吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会第八 次会议决议召开公司2024年第一次临时股东大会（以下简称"本次股东大会"）， 本次股东大会采用现场投票和网络投票相结合的表决方式，现将有关事项通知如 下： 一、召开会议基本情况 1、股东大会届次：2024年第一次临时股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：经公司第十一届董事会第八次会议审议通过， 决定召开公司2024年第一次临时股东大会，本次 ...

Investment Rating - The report gives an "Accumulate" rating for the company, indicating a positive outlook for future performance [35][156]. Core Insights - The company has a strong historical foundation in the pharmaceutical industry and is actively expanding into the health and wellness sector, leveraging its financial strengths to drive growth [42][50]. - The traditional Chinese medicine segment is expected to maintain a high growth rate, with projected revenue growth rates of 20.7%, 15.5%, and 13.7% for 2023-2025 [154]. - The chemical drug segment is anticipated to recover gradually, with significant growth expected from products like L-lysine and other small varieties [20][107]. - The health and wellness business is experiencing rapid growth, with a revenue increase of 303.76% in the first half of 2023 compared to the previous year [137]. Summary by Sections 1. Company Overview - The company, Jilin Aodong Pharmaceutical Group, has a long history dating back to 1957 and has evolved into a large-scale enterprise focusing on pharmaceuticals and health products [42][50]. - The company has a stable shareholding structure, with key management continuously increasing their stakes, which enhances investor confidence [46][57]. 2. Traditional Chinese Medicine (TCM) - TCM products have shown steady growth, with significant contributions from core products such as Anshen Bnnao Liquid, Xiaoer Chaigui Oral Liquid, and Xuefu Zhuyu Oral Liquid [50][89]. - The company is expanding its production capacity for TCM formula granules, which are expected to capture a larger market share [78][154]. 3. Chemical Drugs - The chemical drug segment has faced challenges due to regulatory impacts but is expected to stabilize and recover, particularly with the removal of certain products from monitoring lists [20][107]. - Sales of L-lysine and other chemical drugs are projected to grow significantly, contributing to the overall revenue recovery [20][107]. 4. Health and Wellness Sector - The health and wellness segment is rapidly expanding, with a focus on dietary supplements and functional foods, which are projected to see substantial revenue growth [137][148]. - The company is leveraging e-commerce and digital marketing strategies to enhance sales in this sector [139]. 5. Financial Performance and Projections - The company forecasts net profits of 2.76 billion, 3.26 billion, and 3.79 billion yuan for 2023-2025, reflecting significant growth rates [22][156]. - The projected total market value of the company is estimated at 223.7 billion yuan, indicating that the current market valuation is undervalued [156].